In this study, we demonstrate that HER2‐positive invasive lobular carcinoma represents a biologically distinct subgroup with poor prognostic features, which differs from HER2‐negative lobular carcinoma in terms of immunophenotype, clinical parameters, and molecular alterations. The gene discussed is ERBB2; the disease is invasive lobular breast carcinoma.